United Therapeutics CEO Martine Rothblatt sells $5.1m in shares

United Therapeutics CEO Martine Rothblatt sold $5.12 million worth of shares on October 6, 2026, as reported by InvestingPro. The shares were sold at prices ranging from $527.36 to $545.51 per share, and the current stock price is $549.16. United Therapeutics' market capitalization is $22.85 billion. The company's recent performance shows a 25% increase in shares over the past year, but the stock appears overvalued according to InvestingPro analysis.

Rothblatt exercised stock options to acquire 9,500 common shares, valued at $1,118,720, through a pre-arranged 10b5-1 trading plan adopted on November 7, 2025. The options were set to expire on various dates between 2021 and 2027. Despite Rothblatt's share sales, management has been actively buying back shares, demonstrating confidence in the company's outlook.

Following the reported transactions, Rothblatt indirectly holds 324,443 shares of common stock. United Therapeutics reported a higher-than-expected earnings per share of $7.27 in its second-quarter 2026 earnings, but revenue fell short of expectations at $783.3 million, down about 2.9% from the $807.05 million forecast. BofA Securities lowered its price target to $559 from $613, while BTIG upgraded the stock to Buy with a $728 price target, highlighting the patent ruling as a significant advantage over competitor Liquidia.

The mixed outlook from analysts includes a Sell rating from Goldman Sachs, a neutral rating from BofA Securities, and an Overweight rating with a $700 price target from Cantor Fitzgerald, following a favorable patent ruling on the company's Tyvaso franchise.